DiaMedica Therapeutics (DMAC) Operating Expenses (2018 - 2026)

DiaMedica Therapeutics has reported Operating Expenses for 9 years, with the latest figure at $10.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 28.71% year-over-year to $10.5 million; the trailing twelve-month figure through Mar 2026 stood at $36.7 million (up 26.31% YoY), and the FY2025 full-year result was $34.4 million, up 28.92% from the prior year.
• Operating Expenses for Q1 2026 stood at $10.5 million, up from $9.2 million in the prior quarter.
• The five-year high for Operating Expenses was $10.5 million in Q1 2026, with the low at $3.1 million in Q3 2022.
• Historically, Operating Expenses has averaged $6.3 million across 5 years, with a median of $5.7 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses fell 8.43% — and 2023, when it surged 64.87%.
• DiaMedica Therapeutics' Operating Expenses stood at $4.0 million in 2022, then jumped by 47.19% to $5.8 million in 2023, then soared by 43.96% to $8.4 million in 2024, then rose by 9.43% to $9.2 million in 2025, then grew by 13.77% to $10.5 million in 2026.
• The last three Operating Expenses figures came in at $10.5 million (Q1 2026), $9.2 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.